Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 4/20 | 0.39 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 3/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933499 | 0.94 | HRH3 (0.42) | HRH3MMP2MMP3CHEK1CHEK2 | |
| SCHEMBL16933631 | 0.91 | CHRM5 (0.39) | HRH3MMP2MMP3CHRM5CHRM1 | |
| SCHEMBL16933481 | 0.91 | CHRM5 (0.40) | HRH3CHRM5CHRM1CHRM3 | |
| SCHEMBL16933479 | 0.91 | CHRM5 (0.40) | HRH3CHRM5CHRM1CHRM3 | |
| SCHEMBL16933687 | 0.86 | CHRM5 (0.42) | HRH3CHRM5CHRM1CHRM3 | |
| SCHEMBL16933578 | 0.85 | HRH3 (0.38) | HRH3MMP2MMP3NR4A2DHODH | |
| SCHEMBL16933545 | 0.83 | CHRM5 (0.41) | CHRM5CHRM1CHRM3 | |
| SCHEMBL16933567 | 0.82 | CHRM5 (0.42) | CHRM5CHRM1CHRM3 | |
| SCHEMBL16007862 | 0.80 | CHRM3 (0.41) | CHRM5CHRM1CHRM3 | |
| SCHEMBL16933585 | 0.80 | CHRM5 (0.37) | CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | HRH3 3525/4885MMP2 1379/4885MMP3 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.